Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2018

View Archived Issues

Sanofi and Revolution Medicines collaborate to develop targeted therapies for multiple cancers

KH-NDTC, novel orally active inverse agonist of ERR-gamma as enhancer for sodium iodide symporter

NT-1654 reduces clinical severity of EAMG in rats

Pilot study to identify novel biomarkers of endometrial cancer and its recurrence following surgery

Novel human T regulatory-selective IL-2 antibody for autoimmune or graft-versus-host diseases

H4:IC31 or BCG vaccination reduces the rate of sustained M. tuberculosis infection in phase II trial

Leukemia cells hitch ride to brain via bone and blood

Synaptic vesicle glycoprotein 2A by PET imaging, a marker of synaptic density in Alzheimer's disease

FDA places partial clinical hold on phase I study of XMT-1522

Toray cleared to begin phase I study of TRK-250 in patients with idiopathic pulmonary fibrosis

Kite and Gadeta to develop novel gamma delta TCR therapies

Mutations in MYF5 gene found to cause ophthalmoplegia with rib and vertebral anomalies

Alligator seeks clearance for phase I study of ATOR-1015

PureTech and Roche collaborate on technology for oral administration of antisense oligonucleotides

Day 150 topline results from phase I/II study of THR-317 in DME confirm safety and tolerability

Institute of Materia Medica of Beijing patents PI3Kalpha inhibitors

Merck & Co. presents HIV-1 protease inhibitors

Glenmark Pharmaceuticals discloses new RORC antagonists

BioMarin Pharmaceutical divulges CGT inhibitors

Epizyme discovers EHMT1 and/or EHMT2 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...